Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.
OBJECTIVE: To test whether the chronic relapsing arthritis induced by immunizing DBA/1 mice with homologous type II collagen is a valuable model for testing disease-modifying antiarthritic drugs. METHODS: Six-week-old male DBA/1 mice were immunized with murine type II collagen in Freund's compl...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2001
|
| _version_ | 1826282424116445184 |
|---|---|
| author | Malfait, A Williams, R Malik, A Maini, R Feldmann, M |
| author_facet | Malfait, A Williams, R Malik, A Maini, R Feldmann, M |
| author_sort | Malfait, A |
| collection | OXFORD |
| description | OBJECTIVE: To test whether the chronic relapsing arthritis induced by immunizing DBA/1 mice with homologous type II collagen is a valuable model for testing disease-modifying antiarthritic drugs. METHODS: Six-week-old male DBA/1 mice were immunized with murine type II collagen in Freund's complete adjuvant, resulting in a chronic relapsing polyarthritis in >80% of the mice 4 weeks after immunization. At the onset of clinical arthritis, mice were treated for 4 weeks with different treatments, including anti-tumor necrosis factor (anti-TNF) and antiinterleukin-12 (anti-IL-12) antibodies, salbutamol, or indomethacin. Alternatively, treatment was administered as a pulse at the beginning of clinical arthritis. Pulse treatments tested included anti-CD3 in combination with anti-TNF, anti-TNF alone, and anti-CD4, either alone or in combination with anti-TNF. After 4 weeks of arthritis, mice were killed and hind paws were assessed histologically for joint damage. RESULTS: Anti-TNF and salbutamol both suppressed clinical arthritis more effectively than indomethacin and, moreover, protected the joints from damage, whereas indomethacin did not. Anti-IL-12 treatment initiated after the onset of clinical symptoms accelerated disease. Pulse therapy with anti-CD3 plus anti-TNF was found to induce remission, clinically as well as histologically, whereas a pulse with either anti-CD4, anti-TNF, or the combination of anti-CD4 plus anti-TNF was less effective. CONCLUSION: Chronic relapsing homologous collagen-induced arthritis is a valuable model for identifying remission-inducing antiarthritic drugs and has predictive value with respect to their joint-protective potency. |
| first_indexed | 2024-03-07T00:43:38Z |
| format | Journal article |
| id | oxford-uuid:83e58c10-01c1-4cbe-b944-2c93c22475a2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:43:38Z |
| publishDate | 2001 |
| record_format | dspace |
| spelling | oxford-uuid:83e58c10-01c1-4cbe-b944-2c93c22475a22022-03-26T21:47:23ZChronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:83e58c10-01c1-4cbe-b944-2c93c22475a2EnglishSymplectic Elements at Oxford2001Malfait, AWilliams, RMalik, AMaini, RFeldmann, MOBJECTIVE: To test whether the chronic relapsing arthritis induced by immunizing DBA/1 mice with homologous type II collagen is a valuable model for testing disease-modifying antiarthritic drugs. METHODS: Six-week-old male DBA/1 mice were immunized with murine type II collagen in Freund's complete adjuvant, resulting in a chronic relapsing polyarthritis in >80% of the mice 4 weeks after immunization. At the onset of clinical arthritis, mice were treated for 4 weeks with different treatments, including anti-tumor necrosis factor (anti-TNF) and antiinterleukin-12 (anti-IL-12) antibodies, salbutamol, or indomethacin. Alternatively, treatment was administered as a pulse at the beginning of clinical arthritis. Pulse treatments tested included anti-CD3 in combination with anti-TNF, anti-TNF alone, and anti-CD4, either alone or in combination with anti-TNF. After 4 weeks of arthritis, mice were killed and hind paws were assessed histologically for joint damage. RESULTS: Anti-TNF and salbutamol both suppressed clinical arthritis more effectively than indomethacin and, moreover, protected the joints from damage, whereas indomethacin did not. Anti-IL-12 treatment initiated after the onset of clinical symptoms accelerated disease. Pulse therapy with anti-CD3 plus anti-TNF was found to induce remission, clinically as well as histologically, whereas a pulse with either anti-CD4, anti-TNF, or the combination of anti-CD4 plus anti-TNF was less effective. CONCLUSION: Chronic relapsing homologous collagen-induced arthritis is a valuable model for identifying remission-inducing antiarthritic drugs and has predictive value with respect to their joint-protective potency. |
| spellingShingle | Malfait, A Williams, R Malik, A Maini, R Feldmann, M Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. |
| title | Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. |
| title_full | Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. |
| title_fullStr | Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. |
| title_full_unstemmed | Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. |
| title_short | Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. |
| title_sort | chronic relapsing homologous collagen induced arthritis in dba 1 mice as a model for testing disease modifying and remission inducing therapies |
| work_keys_str_mv | AT malfaita chronicrelapsinghomologouscollageninducedarthritisindba1miceasamodelfortestingdiseasemodifyingandremissioninducingtherapies AT williamsr chronicrelapsinghomologouscollageninducedarthritisindba1miceasamodelfortestingdiseasemodifyingandremissioninducingtherapies AT malika chronicrelapsinghomologouscollageninducedarthritisindba1miceasamodelfortestingdiseasemodifyingandremissioninducingtherapies AT mainir chronicrelapsinghomologouscollageninducedarthritisindba1miceasamodelfortestingdiseasemodifyingandremissioninducingtherapies AT feldmannm chronicrelapsinghomologouscollageninducedarthritisindba1miceasamodelfortestingdiseasemodifyingandremissioninducingtherapies |